144 related articles for article (PubMed ID: 21105683)
21. Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease.
Portelius E; Olsson M; Brinkmalm G; Rüetschi U; Mattsson N; Andreasson U; Gobom J; Brinkmalm A; Hölttä M; Blennow K; Zetterberg H
J Alzheimers Dis; 2013; 33(1):85-93. PubMed ID: 22886024
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Aβ₁-₄₂ fibril formation in vitro.
Wei CW; Peng Y; Zhang L; Huang Q; Cheng M; Liu YN; Li J
Bioorg Med Chem Lett; 2011 Oct; 21(19):5818-21. PubMed ID: 21855336
[TBL] [Abstract][Full Text] [Related]
23. Solid-state NMR sequential assignment of Osaka-mutant amyloid-beta (Aβ1-40 E22Δ) fibrils.
Huber M; Ovchinnikova OY; Schütz AK; Glockshuber R; Meier BH; Böckmann A
Biomol NMR Assign; 2015 Apr; 9(1):7-14. PubMed ID: 24395155
[TBL] [Abstract][Full Text] [Related]
24. Engineering of a peptide probe for β-amyloid aggregates.
Aoraha E; Candreva J; Kim JR
Mol Biosyst; 2015 Aug; 11(8):2281-9. PubMed ID: 26073444
[TBL] [Abstract][Full Text] [Related]
25. High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer.
Robb E; Perez K; Hung LW; Masters CL; Barnham KJ; Cherny RA; Bush AI; Adlard PA; Finkelstein DI
J Alzheimers Dis; 2015; 44(1):69-78. PubMed ID: 25182735
[TBL] [Abstract][Full Text] [Related]
26. Preparation of pure populations of covalently stabilized amyloid β-protein oligomers of specific sizes.
Hayden EY; Conovaloff JL; Mason A; Bitan G; Teplow DB
Anal Biochem; 2017 Feb; 518():78-85. PubMed ID: 27810329
[TBL] [Abstract][Full Text] [Related]
27. A peptide probe for detection of various beta-amyloid oligomers.
Hu Y; Su B; Zheng H; Kim JR
Mol Biosyst; 2012 Oct; 8(10):2741-52. PubMed ID: 22832997
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of a highly soluble Aβ
LeVatte MA; Lipfert M; Ladner-Keay C; Wishart DS
Protein Expr Purif; 2019 Dec; 164():105480. PubMed ID: 31425755
[TBL] [Abstract][Full Text] [Related]
29. Aβ42 and Aβ40: similarities and differences.
Qiu T; Liu Q; Chen YX; Zhao YF; Li YM
J Pept Sci; 2015 Jul; 21(7):522-9. PubMed ID: 26018760
[TBL] [Abstract][Full Text] [Related]
30. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity.
Ono K; Condron MM; Teplow DB
J Biol Chem; 2010 Jul; 285(30):23186-97. PubMed ID: 20452980
[TBL] [Abstract][Full Text] [Related]
31. Analysis of beta amyloid peptides employing the small probe molecules.
Hong HB; Nam IH; Sohn SW; Song KB
J Biomed Nanotechnol; 2013 Jun; 9(6):1088-91. PubMed ID: 23858974
[TBL] [Abstract][Full Text] [Related]
32. Association thermodynamics and conformational stability of beta-sheet amyloid beta(17-42) oligomers: effects of E22Q (Dutch) mutation and charge neutralization.
Blinov N; Dorosh L; Wishart D; Kovalenko A
Biophys J; 2010 Jan; 98(2):282-96. PubMed ID: 20338850
[TBL] [Abstract][Full Text] [Related]
33. Antiparallel β-Sheet Structure within the C-Terminal Region of 42-Residue Alzheimer's Amyloid-β Peptides When They Form 150-kDa Oligomers.
Huang D; Zimmerman MI; Martin PK; Nix AJ; Rosenberry TL; Paravastu AK
J Mol Biol; 2015 Jul; 427(13):2319-28. PubMed ID: 25889972
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease.
Streltsov VA; Varghese JN; Masters CL; Nuttall SD
J Neurosci; 2011 Jan; 31(4):1419-26. PubMed ID: 21273426
[TBL] [Abstract][Full Text] [Related]
35. Understanding amyloid fibril nucleation and aβ oligomer/drug interactions from computer simulations.
Nguyen P; Derreumaux P
Acc Chem Res; 2014 Feb; 47(2):603-11. PubMed ID: 24368046
[TBL] [Abstract][Full Text] [Related]
36. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
Watson D; Castaño E; Kokjohn TA; Kuo YM; Lyubchenko Y; Pinsky D; Connolly ES; Esh C; Luehrs DC; Stine WB; Rowse LM; Emmerling MR; Roher AE
Neurol Res; 2005 Dec; 27(8):869-81. PubMed ID: 16354549
[TBL] [Abstract][Full Text] [Related]
37. Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β derived diffusible ligands in Alzheimer's disease.
Lee MC; Yu WC; Shih YH; Chen CY; Guo ZH; Huang SJ; Chan JCC; Chen YR
Sci Rep; 2018 Mar; 8(1):4772. PubMed ID: 29555950
[TBL] [Abstract][Full Text] [Related]
38. Peptide backbone modification in the bend region of amyloid-β inhibits fibrillogenesis but not oligomer formation.
Johnson EC; Lanning JD; Meredith SC
J Pept Sci; 2016 May; 22(5):368-73. PubMed ID: 27114096
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of amyloid-β aggregation in Alzheimer's disease.
Wang Q; Yu X; Li L; Zheng J
Curr Pharm Des; 2014; 20(8):1223-43. PubMed ID: 23713775
[TBL] [Abstract][Full Text] [Related]
40. Amyloid β-protein assembly: The effect of molecular tweezers CLR01 and CLR03.
Zheng X; Liu D; Klärner FG; Schrader T; Bitan G; Bowers MT
J Phys Chem B; 2015 Apr; 119(14):4831-41. PubMed ID: 25751170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
